Amiodarone Pulmonary Toxicity

Authors, Journal, Affiliations, Type, DOI

• Authors: Philippe Camus, William J. Martin II, Edward C. Rosenow III
• Journal: Clinics in Chest Medicine
• Year / Volume: 2004, Vol. 25, No. 1, pp. 65–75
• Affiliations: Centre Hospitalier et Université de Bourgogne, Dijon, France; University of Cincinnati; Mayo School of Medical Education, Rochester MN
• Type: Narrative review (authoritative — Camus is the reference expert in drug-induced lung disease)
• DOI: 10.1016/S0272-5231(03)00144-8

Overview

Amiodarone pulmonary toxicity (APT) affects 1–15% of treated patients, driven by extreme tissue accumulation (100–500× lung-to-serum ratio for amiodarone and desethylamiodarone) that persists for up to 1 year after drug cessation. APT encompasses six distinct clinical patterns ranging from subacute infiltrative pneumonitis to irreversible fibrosis, with diagnosis by exclusion and DLCO as the earliest functional marker. High-concentration oxygen and thoracic surgery are specific ARDS triggers. Hospitalization mortality ranges 21–33%; corticosteroids are required for 6–12 months and must be tapered slowly — early withdrawal causes recurrence.

Keywords

Amiodarone, amiodarone pneumonitis, drug-induced lung injury, pulmonary toxicity, interstitial lung disease, ARDS, pulmonary fibrosis

Key Takeaways

Pharmacokinetics Relevant to Pulmonary Toxicity

• Amiodarone (Am) and its active metabolite desethylamiodarone (DEAm) are cationic amphiphilics that sequester extensively in lung, liver, skin, thyroid, and eye
• Lung tissue concentration is 100-fold (Am) and 500-fold (DEAm) above serum concentrations — this magnifies toxicity even at therapeutic serum levels
• Am and DEAm localise in cell lysosomes → block turnover of endogenous phospholipids → characteristic foamy lipid-laden macrophages with whorled lamellar membranous inclusions in BAL and lung tissue
• Myelinic figures (foamy macrophages) indicate Am exposure, NOT necessarily toxicity; however, their absence makes classic APT unlikely
• Elevated DEAm (not Am) plasma levels are found in patients with APT vs unaffected patients — Am plasma level does not reliably predict APT
• Drug persists in lung tissue up to 1 year after cessation — explaining why withdrawal alone may be insufficient and why recurrence can occur long after stopping

Epidemiology and Risk Factors

• Cumulative prevalence 1–15%; dose is linked but NOT strictly the determining factor — APT occurs even at 200 mg/day
  • 0.1–0.5% at ≤200 mg/day; 5–15% at ≥500 mg/day; up to 50% at 1200 mg/day
• More common in men; unusual in patients <40 years; risk increases with age
• Risk factors: cumulative exposure (dose × duration), poor baseline pulmonary function, pulmonary emphysema, prior pneumonectomy
• High-concentration oxygen + amiodarone = major ARDS risk: perioperative exposure to high FiO₂ (cardiac or pulmonary surgery, single-lung ventilation with 100% O₂, ICD implantation) is a specific ARDS trigger
• Iodinated contrast media: 2 fatal ARDS cases reported; caution advised though further cases are unreported
• Diagnosis typically made ~2 months after symptom onset — ample room for earlier detection

Clinical and Imaging Patterns of APT (Six Patterns)

1. Subacute Infiltrative Pneumonitis (Most Common)

• Patchy or diffuse bilateral infiltrates; alveolar, ground-glass, or mottling opacities
• High attenuation on CT — characteristic due to iodine content; more consistent in advanced disease
• Asymmetrical involvement is typical (unlike most other drug-induced lung diseases); right upper lobe predilection
• Subpleural distribution predominant (18/20 in one HRCT series)
• HRCT: ground-glass opacities, inter/intralobular septal thickening, patchy small alveolar shadows, occasional pleural thickening
• Exudative pleural effusion in up to 1/3 of cases; pericardial effusion occasional

2. Organising Pneumonia Pattern

• Migratory or fixed alveolar opacities; histologically: endoluminal fibrosis + interstitial inflammation + foam cells
• Clinically/radiologically indistinguishable from idiopathic organising pneumonia
• Opacities can migrate even on corticosteroids until amiodarone is stopped; requires prolonged steroid therapy to prevent relapse

3. Pulmonary Fibrosis

• Estimated frequency ~0.1%; develops in 5–7% following classic pneumonitis or de novo
• Dense bibasilar reticular opacities, coarse crackles, significant hypoxemia, weight loss
• HRCT: coarse interstitial reticular and perilobular opacities, traction bronchiectases at lung bases; honeycombing uncommon at diagnosis
• Irreversible — limited or transient corticosteroid response; adverse impact on life expectancy

4. Pulmonary Nodules / Masses (6–12% of APT)

• Single mass or multiple subpleural masses with increased attenuation on HRCT
• Abut the pleura → pleuritic chest pain or friction rub
• Can mimic pulmonary infarction, pneumonia, organising pneumonia, peripheral carcinoma, or lymphoma

5. ARDS (Post-Thoracic Surgery Pattern)

• Occurs almost exclusively following cardiac or pulmonary surgery; reported in up to 10% after ICD implantation
• Rapidly progressive respiratory failure; diffuse alveolar opacities; requires mechanical ventilation; responds poorly to corticosteroids
• Fatality rate approximately 50%
• ARDS can also be the terminal event in Am-induced fibrosis

6. Subclinical APT

• Normal chest radiograph but ground-glass opacities, small alveolar opacities, or increased septal lines on HRCT
• Increased inflammatory cells in BAL; positive gallium scan in asymptomatic patients
• Reversible upon drug cessation; significance for progression to overt APT is unclear

Other Respiratory Adverse Effects

• Alveolar haemorrhage: unusual; differentiate from haemorrhagic pulmonary oedema and anticoagulant effects
• Pleural effusion: exudative (protein 2.8–5.5 g/dL); lymphocyte or lymphocyte+neutrophil predominance; foam cells may be present in pleural fluid
• Pleural thickening: common, especially adjacent to dense infiltrates; may persist after pulmonary clearing
• Drug-induced lupus: rare; pleural or pleuropericardial effusions + positive ANA → resolves after drug withdrawal

Pulmonary Function Testing

• Baseline PFTs (including DLCO) recommended before starting amiodarone
• DLCO is the earliest and most sensitive marker of APT:
  • Best sensitivity threshold: ≥15% decrease
  • Best specificity threshold: ≥30% decrease
  • Isolated DLCO decrease → overt APT develops in only 1/3 of such patients
  • Isolated DLCO decrease WITHOUT clinical/imaging evidence should NOT prompt discontinuation
  • Stable DLCO = absence of clinically meaningful APT
• Serial PFTs in high-risk patients (emphysema, poor baseline PF, prior pneumonectomy); every 3–6 months
• Routine serial PFTs in standard low-dose patients: probably unrewarding (disease uncommon in this subset)
• Caveat: DLCO interpretation is confounded in patients with background emphysema

Bronchoalveolar Lavage (BAL)

• Foam cells with lamellar inclusions = marker of Am exposure only, not toxicity (present in all chronically exposed patients)
• Absence of foam cells makes classic APT unlikely
• BAL cellular pattern: variable — may show normal distribution, or increase in CD8+ lymphocytes, neutrophils, or mixed; CD8+ alone no longer considered diagnostic
• Shorter time to pneumonitis onset associated with lymphocytosis in BAL
• No consistent BAL pattern for Am-induced ARDS or fibrosis

Histopathology

• Not required in every patient; consider when diagnosis required urgently (pre-cardiac surgery, no improvement at 1–2 months)
• Caution: open lung biopsy in Am-treated patients carries risk of post-procedure deterioration
• Classic APT: septal thickening, interstitial oedema, nonspecific inflammation/fibrosis, intraalveolar foamy macrophages, hyperplasia of type II cells
• Organising pneumonia pattern: endoluminal fibrosis + interstitial inflammation + foam cells
• Am-induced fibrosis: severe interstitial fibrosis + type II cell hyperplasia/dysplasia + foamy alveolar macrophages
• ARDS: active or resolving diffuse alveolar damage + hyaline membranes

Diagnostic Work-up

1. Drug history + detailed imaging (CXR + HRCT)
2. Pulmonary function testing (especially DLCO vs baseline)
3. BAL
4. Diuresis trial — partial clearing suggests LV failure component; persistent opacities after diuresis → continue considering APT
5. If confidence is sufficient: discontinue Am under cardiological guidance; observe 1–2 months for improvement
6. Add corticosteroids if substantial imaging involvement or hypoxaemia
7. If no improvement at 1–2 months after stopping Am + corticosteroids → consider alternative diagnoses
8. Lung biopsy if: (a) urgent diagnosis needed pre-surgery or when Am cannot be stopped; (b) no improvement by 1–2 months

Management and Outcome

• Discontinue amiodarone (under cardiological guidance): sole intervention sufficient only if disease extent is limited
• Corticosteroids (no controlled RCT but strong observational evidence):
  • Starting dose: prednisolone 0.75–1 mg/kg/day
  • Maintain initial dose until definite clinical + radiographic response
  • Taper slowly and prudently — estimated minimum 6 months, often 1 year
  • Early withdrawal (2–3 months) → recurrence; recurrence pattern may be more severe than initial episode, potentially fatal
  • Monitor for corticosteroid adverse effects in long-term users (opportunistic infections)
• Alternative to discontinuation: dose reduction (e.g., halved) + corticosteroids — effective in selected patients with refractory arrhythmias
• Radiological follow-up: complete clearing in ~85% of patients at 1–3 months; residual opacities persist in remainder
• DLCO: may remain persistently decreased despite imaging clearance (combined effect of APT + emphysema)
• Mortality: 21–33% in hospitalised patients; worse prognosis with background COPD
• Rechallenge: recurrence of symptoms and radiographic abnormalities in ~2/3 of patients who resume Am; monitor DLCO for early detection; gallium scan as confirmatory test

Prevention and Early Detection

• Select patients carefully for amiodarone; use lowest effective dose
• Baseline CXR + PFTs (including DLCO) mandatory before starting
• High-risk patients (poor lung function, emphysema, prior pneumonectomy): more frequent follow-up (PFTs + imaging every 3–6 months)
• Standard-dose patients: routine serial PFTs probably unrewarding but patient education and watchful waiting required
• Avoid high-concentration O₂ in Am-treated patients undergoing surgery
• Caution with iodinated contrast media in Am-treated patients

Limitations of the Document

• 2004 review — predates modern HRCT techniques and novel APT biomarkers (KL-6 validation, SP-D, quantitative CT)
• No controlled trials for corticosteroid efficacy — all evidence observational or case series
• Dosing recommendations for corticosteroids based on expert consensus, not RCT
• DLCO thresholds from single prospective study (Magro et al., JACC 1988; n not specified)
• Prevalence estimates span wide ranges reflecting heterogeneous dosing and monitoring across studies
• Iodinated contrast media risk based on only 2 reported cases

Key Concepts Mentioned

• concepts/Amiodarone-Pulmonary-Toxicity — primary topic; full clinical pattern catalogue, diagnostic algorithm, management
• concepts/Amiodarone-Induced-Thyroid-Disorders — co-occurring toxicity; thyrotoxicosis can exacerbate dyspnoea in APT

Key Entities Mentioned

• entities/Amiodarone — causative drug; pulmonary toxicity section updated

Wiki Pages Updated

• wiki/sources/amiodarone-pulmonary-clin-chest-2004.md — created (this file)
• wiki/concepts/Amiodarone-Pulmonary-Toxicity.md — created
• wiki/entities/Amiodarone.md — pulmonary toxicity section expanded; source added
• wiki/wikiindex.md — new concept entry added
• wiki/sourceindex.md — new source entry added